Company Overview of VGX Pharmaceuticals, LLC
VGX Pharmaceuticals, LLC discovers and develops vaccines and therapies for infectious diseases and cancer. The company’s phase I clinical product portfolio includes PENNVAX-B, a DNA vaccine for the prevention of HIV; VGX-3100, a therapeutic DNA vaccine for cervical cancer; and the CELLECTRA electroporation DNA delivery device. VGX Pharmaceuticals, LLC also develops VGX-1027, a small molecule drug in phase I clinical study for inflammatory diseases; and VGX-3400, a preventative DNA vaccine for avian influenza. The company was founded in 2000 and is headquartered in Blue Bell, Pennsylvania. As of June 1, 2009, VGX Pharmaceuticals, LLC operates as a subsidiary of Inovio Pharmaceuticals, Inc.
450 Sentry Parkway
Blue Bell, PA 19422
Founded in 2000
Key Executives for VGX Pharmaceuticals, LLC
Similar Private Companies By Industry
|NitroMed, Inc.||United States|
|Dual Therapeutics, LLC||United States|
|Teotten Diagnostics, Inc.||United States|
|Regent GLSC Technologies, Inc.||United States|
|Biochemie US, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact VGX Pharmaceuticals, LLC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.